Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC)

European Journal of Cancer

Volumn 51, Issue 14, 2015, Pages 1927-1936

  Heinemann, Volker ^a   Stintzing, Sebastian ^a   Modest, Dominik P ^a   Giessen Jung, Clemens ^a   Michl, Marlies ^a   Mansmann, Ulrich R ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cetuximab; Chemotherapy; Depth of response; Early tumour shrinkage; Metastatic colorectal cancer; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL DECISION MAKING; CLINICAL TRIAL (TOPIC); DEPTH OF RESPONSE; EARLY TUMOR SHRINKAGE; HUMAN; METASTATIC COLORECTAL CANCER; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SYSTEMATIC REVIEW; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; COLORECTAL NEOPLASMS; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG EFFECTS; METASTASIS; MOLECULARLY TARGETED THERAPY; MORTALITY; PATHOLOGY; RISK FACTOR; SURVIVAL; TIME; TREATMENT OUTCOME; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; MOLECULAR TARGETED THERAPY; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84939475603     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.06.116     Document Type: Review

References (48)

1. A. Jemal Global cancer statistics (vol. 61, p. 69, 2011) Cancer J Clin 61 2 2011 134-134
2. J. Ferlay, H.R. Shin, F. Bray, D. Forman, C. Mathers, and D.M. Parkin Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer 127 12 2010 2893 2917
3. B. Nordlinger, E. Van Cutsem, T. Gruenberger, B. Glimelius, G. Poston, P. Rougier, and et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel Ann Oncol 20 6 2009 985 992
4. E. Van Cutsem, B. Nordlinger, A. Cervantes, and E.G.W. Grp Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment Ann Oncol 21 2010 v93 v97
5. H.J. Schmoll, E. Van Cutsem, A. Stein, V. Valentini, B. Glimelius, K. Haustermans, and et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making Ann Oncol 23 10 2012 2479 2516
6. E. Van Cutsem, M. Dicato, N. Arber, J. Berlin, A. Cervantes, F. Ciardiello, and et al. Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009 Ann Oncol 21 2010 1 10
7. L.C. Ye, T.S. Liu, L. Ren, Y. Wei, D.X. Zhu, S.Y. Zai, and et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases J Clin Oncol 31 16 2013 1931 1938
8. G. Folprecht, T. Gruenberger, W.O. Bechstein, H.R. Raab, F. Lordick, J.T. Hartmann, and et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial Lancet Oncol 11 1 2010 38 47
9. E. Van Cutsem, C.H. Kohne, E. Hitre, J. Zaluski, C.R. Chang Chien, A. Makhson, and et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 14 2009 1408 1417
10. C. Bokemeyer, I. Bondarenko, A. Makhson, J.T. Hartmann, J. Aparicio, F. de Braud, and et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 27 5 2009 663 671
11. L.B. Saltz, S. Clarke, E. Diaz-Rubio, W. Scheithauer, A. Figer, R. Wong, and et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 12 2008 2013 2019
12. J.Y. Douillard, K.S. Oliner, S. Siena, J. Tabernero, R. Burkes, M. Barugel, and et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer N Engl J Med 369 11 2013 1023 1034
13. H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, and et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 23 2004 2335 2342
14. V. Heinemann, L.F. von Weikersthal, T. Decker, A. Kiani, U. Vehling-Kaiser, S.E. Al-Batran, and et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial Lancet Oncol 15 10 2014 1065 1075
15. A.P. Venook, D. Niedzwiecki, H.J. Lenz, F. Innocenti, M.R. Mahoney, B.H. O'Neil, and et al. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC) J Clin Oncol 32 Suppl. 2014 5s [abstr. LBA3]
16. A.P. Venook, and J. Tabernero Progression-free survival: helpful biomarker or clinically meaningless end point? J Clin Oncol 2014
17. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, L. Rubinstein, and et al. New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 3 2000 205 216
18. E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, and et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2 2009 228 247
19. Y.S. Chun, J.N. Vauthey, P. Boonsirikamchai, D.M. Maru, S. Kopetz, M. Palavecino, and et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases JAMA 302 21 2009 2338 2344
20. T. Hamaoka, C.M. Costelloe, J.E. Madewell, P. Liu, D.A. Berry, R. Islam, and et al. Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer Br J Cancer 102 4 2010 651 657
21. S.J. Mandrekar, M.W. An, J. Meyers, A. Grothey, J. Bogaerts, and D.J. Sargent Evaluation of alternate categorical tumor metrics and cut points for response categorization using the RECIST 1.1 Data Warehouse J Clin Oncol 32 8 2014 841-+
22. R. Ricotta, A. Vanzulli, M. Moroni, B. Colnago, M. Oriani, M. Nichelatti, and et al. Magnetic resonance imaging as an early indicator of clinical outcome in patients with metastatic colorectal carcinoma treated with cetuximab or panitumumab Clin Colorect Cancer 12 1 2013 45 53
23. C. Suzuki, L. Blomqvist, A. Sundin, H. Jacobsson, P. Bystrom, A. Berglund, and et al. The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy Ann Oncol 23 4 2012 948-U7
24. C. Giessen, R.P. Laubender, L. Fischer von Weikersthal, A. Schalhorn, D.P. Modest, S. Stintzing, and et al. Early tumor shrinkage in metastatic colorectal cancer: retrospective analysis from an irinotecan-based randomized first-line trial Cancer Sci 104 6 2013 718 724
25. H. Piessevaux, M. Buyse, W. De Roock, H. Prenen, M. Schlichting, E. Van Cutsem, and et al. Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial) Ann Oncol 20 8 2009 1375 1382
26. D.P. Modest, R.P. Laubender, S. Stintzing, C. Giessen, C. Schulz, M. Haas, and et al. Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: an analysis of the German AIO KRK 0104 trial Acta Oncol 52 5 2013 956 962
27. H. Piessevaux, M. Buyse, M. Schlichting, E. Van Cutsem, C. Bokemeyer, S. Heeger, and et al. Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab J Clin Oncol 31 30 2013 3764-+
28. U.R. Mansmann, U. Sartorius, R.P. Laubender, C.A. Giessen, R. Esser, and V. Heinemann Quantitative analysis of the impact of deepness of response on post-progression survival time following first-line treatment in patients with mCRC J Clin Oncol 31 15 2013
29. M. Peeters, T. Price, A. Cervantes, A. Sobrero, M. Ducreux, T. Andre, and et al. Tumour shrinkage and response outcomes during second-line panitumumab + FOLFIRI vs FOLFIRI treatment Ann Oncol 2014 ESMO 2014 suppl. (poster 546P)
30. S. Bazarbashi, A. Aljubran, A. Al Zahrani, W. Edesa, M. Nabil-Ahmed, and M. Shoukri Early tumor shrinkage versus early response as a predictor for overall survival (OS) in patients with metastatic colorectal cancer (mCRC) treated with triplet chemotherapy regimens (TCR) J Clin Oncol 32 Suppl. 2014 [abstr. e14580]
31. J. Ichante, A. Adenis, D. Malka, E. Francois, E. Boucher, B. Chauffert, and et al. Impact of early tumor shrinkage on long-term outcome in metastatic colorectal cancer (mCRC) treated with 5FU plus irinotecan plus leucovorin (FOLFIRI) or capecitabine plus irinotecan XELIRI plus bevacizumab J Clin Oncol 29 15 2011
32. C. Cremolini, F. Loupakis, S. Lonardi, P. Trenta, C. Antoniotti, G. Masi, and et al. Early tumor shrinkage (ETS) and deepness of response (DoR) to predict progression-free, postprogression, and overall survival: Results from the phase III TRIBE trial J Clin Oncol 32 3 2014
33. L. Fischer von Weikersthal, A. Schalhorn, M. Stauch, D. Quietzsch, P.A. Maubach, H. Lambertz, and et al. Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer Eur J Cancer 47 2 2011 206 214
34. N. Moosmann, L.F. von Weikersthal, U. Vehling-Kaiser, M. Stauch, H.G. Hass, H. Dietzfelbinger, and et al. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104 - a randomized trial of the German AIO CRC study group J Clin Oncol 29 8 2011 1050 1058
35. A. Tsuji, M. Nakamura, Y. Sunakawa, M. Kochi, T. Denda, T. Yamaguchi, and et al. A phase II study of cetuximab and mFOLFOX6 in mCRC including prospective early tumor shrinkage analysis (JACCRO-CC05) P-0208 Ann Oncol 24 Suppl. 4 2013 iv94 iv95
36. L.C. Ye, Y. Wei, D.X. Zhu, T. Chen, and J. Xu Impact of early tumor shrinkage on clinical outcome in wild-type-KRAS colorectal liver metastases treated with cetuximab J Gastroenterol Hepatol 2014
37. J.Y. Douillard, S. Siena, J. Cassidy, J. Tabernero, R. Burkes, M. Barugel, and et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study J Clin Oncol 28 31 2010 4697 4705
38. J. Douillard, S. Siena, M. Peeters, R. Koukakis, J.H. Terwey, and J. Tabernero Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer Eur J Cancer 51 10 2015 1231 1242
39. D. Cunningham, Y. Humblet, S. Siena, D. Khayat, H. Bleiberg, A. Santoro, and et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 4 2004 337 345
40. M. Peeters, T.J. Price, A. Cervantes, A.F. Sobrero, M. Ducreux, Y. Hotko, and et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer J Clin Oncol 28 31 2010 4706 4713
41. A. Grothey, E.E. Hedrick, R.D. Mass, S. Sarkar, S. Suzuki, R.K. Ramanathan, and et al. Response-independent survival benefit in metastatic colorectal cancer: A comparative analysis of N9741 and AVF2107 J Clin Oncol 26 2 2008 183 189
42. M. Ducreux, A. Adenis, J.P. Pignon, E. Francois, B. Chauffert, J.L. Ichante, and et al. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: Final results from a randomised phase ii study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study) Eur J Cancer 49 6 2013 1236 1245
43. F. Loupakis, C. Cremolini, G. Masi, S. Lonardi, V. Zagonel, L. Salvatore, and et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer N Engl J Med 371 17 2014 1609 1618
44. S. Stintzing, D.P. Modest, L. Fischer von Weikersthal, T. Decker, A. Kiani, U. Vehling-Kaiser, and et al. Independent radiological evaluation of objective response, early tumor shrinkage, and depth of response in FIRE-3 (AIO KRK-0306) in the final RAS evaluable population Ann Oncol 2014 ESMO 2014 (LBA11)
45. F. Rivera, M. Karthaus, J.R. Hecht, G. Fasola, J.L.R. Canon, R. Koukakis, and et al. First-line treatment with modified FOLFOX6 (mFOLFOX6) + panitumumab (pmab) or bevacizumab (bev) in wild-type (WT) RAS metastatic colorectal carcinoma (mCRC): tumor response outcomes beyond RECIST J Clin Oncol 33 Suppl. 3 2015 [abstr. 660]
46. D.W. Sommeijer, Q. Shi, J.P. Meyers, K.M. Sjoquist, P.M. Hoff, M.T. Seymour, and et al. Prognostic value of early objective tumor response (EOTR) to first-line systemic therapy in metastatic colorectal cancer (mCRC): individual patient data (IPD) meta-analysis of randomized trials from the ARCAD database J Clin Oncol 31 15 2013
47. A.P. Venook, and J. Tabernero Progression-free survival: helpful biomarker or clinically meaningless end point? J Clin Oncol 33 1 2015 4 6
48. L. Claret, M. Gupta, K. Han, A. Joshi, N. Sarapa, J. He, and et al. Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer J Clin Oncol 31 17 2013 2110 2114